Cardioprotective effects of hydroxysafflor yellow A on diabetic cardiac insufficiency attributed to up-regulation of the expression of intracellular calcium handling proteins of sarcoplasmic reticulum in rats

Phytother Res. 2008 Aug;22(8):1107-14. doi: 10.1002/ptr.2468.

Abstract

Depressed sarcoplasmic reticulum (SR) Ca(2+)-ATPase (SERCA2a) and Ca(2+)-release channels (ryanodine receptor RyR2) are involved in diabetic cardiomyopathy, however, the implication of intracellular calcium handling proteins in SR is undefined. It was hypothesized that the down-regulation of the intracellular calcium handling proteins of SR is closely related to an up-regulated endothelin (ET) system. Hydroxysafflor yellow A (HSYA) is expected to ameliorate cardiac insufficiency which is mediated by the depressed intracellular calcium handling system in diabetic rat heart. Diabetes was produced in male rats 8 weeks after an injection of streptozotocin (60 mg/kg i.p.) and HSYA was administered (100 mg/kg) by gavage in the last 4 weeks. Hemodynamic and echocardiographic changes, cardiac calcium handling proteins, serum biochemistry, ET system and redox were measured. The compromised cardiac function in diabetic rats was accompanied by a significant down-regulation of the expression of RyR2, FKBP12.6 as well as SERCA2a and PLB. These were closely linked with oxidative stress, an increased ET-1 and up-regulation of ECE, PropreET-1 and iNOS mRNA in diabetic cardiomyopathy. After a 4 week treatment with HSYA, all abnormalities were reversed significantly. In conclusion, diabetic cardiomyopathy was correlated with an abnormal expression of calcium handing proteins in SR and an activated ET-ROS (reactive oxygen species) system in the diabetic affected myocardium. HSYA significantly improved the cardiac function and down-regulated the ET system and ROS pathway, resulting in a reversal of the abnormalities of expression of calcium handing proteins and the cardiac performance in diabetic cardiomyopathy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Administration, Oral
  • Animals
  • Calcium Signaling / drug effects
  • Calcium-Binding Proteins / metabolism
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / physiopathology
  • Cardiotonic Agents / therapeutic use*
  • Chalcone / analogs & derivatives*
  • Chalcone / therapeutic use
  • Diabetes Complications / drug therapy*
  • Diabetes Complications / metabolism
  • Diabetes Complications / physiopathology
  • Diabetes Mellitus, Experimental*
  • Disease Models, Animal
  • Electrocardiography
  • Gene Expression Regulation / drug effects
  • Hemodynamics / drug effects
  • Male
  • Pigments, Biological / therapeutic use*
  • Quinones / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism

Substances

  • Calcium-Binding Proteins
  • Cardiotonic Agents
  • Pigments, Biological
  • Quinones
  • Reactive Oxygen Species
  • hydroxysafflor yellow A
  • Chalcone
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases